logo
Sign InSign Up

ELI LILLY & CO (LLY)

Sector: Healthcare

Financial Fundamentals

findl.com provides a comprehensive suite of standardized financial statement data and an assortment of calculated metrics sourced directly from SEC filings, and meticulously cleansed and verified, ensuring reliability. To get the complete financial statement history in quarterly and annual resolution for LLY, sign up here.

Income Statement

Revenue

$34.1bn

Gross Profit

$27.0bn

Earning before Tax

$6.6bn

Net Income

$5.2bn

Net Income Common Shareholders

$5.2bn

EPS

5.82

Balance Sheet

Cash

$2.8bn

Debt

$25.2bn

Assets

$64.0bn

Liabilities

$53.1bn

Equity

$10.8bn

Enterprise Value

$571.2bn

Cash Flow Statement

Net Cash from Operations

$4.2bn

Net Cash from Investing

$-7.2bn

Net Cash from Financing

$3.5bn

Net Cash Flow

$751.6m

Free Cash Flow

$792.5m

Free Cash Flow per Share

$0.88

Metrics

Price to Equity

0.0m

Price to Equity (Damodaran)

0.0m

Price to Book

51.37

Net Margin

0.15

Return on Equity

0.47

Return on Sales

0.19

Get immediate access to 5-years of reference grade data for LLY for free.

Sign up

Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin''s lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; Foghorn Therapeutics Inc., and PRISM BioLab Co.,Ltd. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Company Info

Industry

Drug Manufacturers - General

Employees

Address

Lilly Corporate Center
Indianapolis, IN 46285
United States

Phone

317 276 2000

Last Updated

2024-02-19

Available Data

Standardized Financial Statements

EOD Price History

Corporate Actions

Institutional Holdings

Insider Transactions

Sign up for free and get immediate access
logo

Radically accessible financial data

Contact Info

findl.com info@findl.com

Explore findl data

DocumentationSupport

Copyright © findl 2024. All rights reserved.

Terms & Use

Privacy Policy